Previous studies haveshown that HIV-infected postmenopausal women have higer rates of bone loss than HIV negative women. No studies so far have analyzed the slope of bone loss across the menopausal transition period. We hypothesized that in HIV infected women BMD decreases in the postmenopausal period and Tenofovir exposure may contribute to this impairment. The aim of the study was to identify predictors of BMD in HIV infected women entering menopause and to evaluate the pre- and post- menopausal BMD change
With advances in combination antiretroviral therapy (cART), people living with HIV are now surviving...
Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss compared with abacavir/lamiv...
ObjectivesWe compared skeletal microarchitecture using trabecular bone score (TBS) and evaluated rel...
Previous studies haveshown that HIV-infected postmenopausal women have higer rates of bone loss than...
HIV-infected postmenopausal women have higer rates of bone loss than HIV negative women. We aimed to...
Menopause is a paradigm of physiological aging involving an impairement in bone metabolism. We hypot...
BACKGROUND: We previously reported lower bone mineral density (BMD) among premenopausal women with H...
: Menopause is a high-risk period for osteoporosis, which may be exacerbated by HIV and/or antiretro...
An estimated 25% of South African women live with human immunodeficiency virus (HIV). Antiretroviral...
The study aimed to determine factors associated with changes in bone mineral density (BMD) and bone ...
Antiretroviral therapy (ART) in people living with human immunodeficiency virus (HIV) is associated ...
The widespread availability of effective antiretroviral therapy (ART) has transformed HIV from a lif...
Initial declines in bone mineral density (BMD) following antiretroviral therapy (ART) initiation in ...
OBJECTIVE: To characterize changes in bone mineral density (BMD) according to race among HIV-infecte...
Background: Tenofovir disoproxil fumarate (TDF) antiretroviral therapy is associated with disruption...
With advances in combination antiretroviral therapy (cART), people living with HIV are now surviving...
Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss compared with abacavir/lamiv...
ObjectivesWe compared skeletal microarchitecture using trabecular bone score (TBS) and evaluated rel...
Previous studies haveshown that HIV-infected postmenopausal women have higer rates of bone loss than...
HIV-infected postmenopausal women have higer rates of bone loss than HIV negative women. We aimed to...
Menopause is a paradigm of physiological aging involving an impairement in bone metabolism. We hypot...
BACKGROUND: We previously reported lower bone mineral density (BMD) among premenopausal women with H...
: Menopause is a high-risk period for osteoporosis, which may be exacerbated by HIV and/or antiretro...
An estimated 25% of South African women live with human immunodeficiency virus (HIV). Antiretroviral...
The study aimed to determine factors associated with changes in bone mineral density (BMD) and bone ...
Antiretroviral therapy (ART) in people living with human immunodeficiency virus (HIV) is associated ...
The widespread availability of effective antiretroviral therapy (ART) has transformed HIV from a lif...
Initial declines in bone mineral density (BMD) following antiretroviral therapy (ART) initiation in ...
OBJECTIVE: To characterize changes in bone mineral density (BMD) according to race among HIV-infecte...
Background: Tenofovir disoproxil fumarate (TDF) antiretroviral therapy is associated with disruption...
With advances in combination antiretroviral therapy (cART), people living with HIV are now surviving...
Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss compared with abacavir/lamiv...
ObjectivesWe compared skeletal microarchitecture using trabecular bone score (TBS) and evaluated rel...